首页> 美国卫生研究院文献>Acta Bio Medica : Atenei Parmensis >Post-surgical intestinal dysbiosis: use of an innovative mixture (Lactobacillus plantarum LP01 Lactobacillus lactis subspecies cremoris LLC02 Lactobacillus delbrueckii LDD01)
【2h】

Post-surgical intestinal dysbiosis: use of an innovative mixture (Lactobacillus plantarum LP01 Lactobacillus lactis subspecies cremoris LLC02 Lactobacillus delbrueckii LDD01)

机译:术后肠道营养不良:使用创新的混合物(植物乳杆菌LP01乳酸乳杆菌creemoris LLC02亚种德氏乳杆菌LDD01)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abdominal surgery represents a high risk for hospital-acquired infections and complication that may compromise the surgery outcome. Patients with recent abdominal surgery have an intestinal dysbiosis. There is evidence that probiotics may counterbalance the impaired microbiota. Therefore, the current survey evaluated the efficacy and safety of Abincol®,an oral nutraceuticalcontaining a probiotic mixture with LP01 (1 billion of living cells), LLC02 (800 millions of living cells), and LDD01 (200 millions of living cells), in 612 outpatients (344 males and 268 females, mean age 58 years) undergoing digestive surgery. Patients took 1 stick/daily for 8 weeks. Abincol® significantly diminished the presence and the severity of intestinal symptoms and improved stool form. In conclusion, the current survey suggests that Abincol® may be considered an effective and safe therapeutic option in the management of patients undergoing digestivesurgery. ( )
机译:腹部手术代表医院获得性感染和并发症的高风险,可能会影响手术效果。最近进行腹部手术的患者患有肠道营养不良。有证据表明益生菌可以抵消受损的微生物群。因此,本次调查评估了含有益生菌混合物与LP01(10亿个活细胞),LLC02(8亿个活细胞)和LDD01(2亿个活细胞)的益生菌混合物的口服保健食品Abincol®的功效和安全性。 612名接受消化道手术的门诊病人(344例男性和268例女性,平均年龄58岁)。患者每天服用1支棍子,持续8周。 Abincol®显着减少了肠道症状的出现和严重程度,并改善了粪便形式。总而言之,当前调查表明,在消化外科手术患者的治疗中,Abincol®可被视为一种有效且安全的治疗选择。 ()

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号